Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Esophagus
Erschienen in: Esophagus 2/2018

16.12.2017 | Review Article

Angiogenic factors: role in esophageal cancer, a brief review

verfasst von: Kátia Ladeira, Filipa Macedo, Adhemar Longatto-Filho, Sandra F. Martins

Erschienen in: Esophagus | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Esophageal cancer has an aggressive behavior with rapid tumor mass growth and frequently poor prognosis; it is known as one of the most fatal types of cancer worldwide. The identification of potential molecular markers that can predict the response to treatment and the prognosis of this cancer has been subject of a vast investigation in the recent years. Among several molecules, various angiogenic factors that are linked to the tumor development, growth, and invasion, such as VEGF, HGF, angiopoietin-2, IL-6, and TGF-B1, were investigated. In this paper, the authors sought to review the role of these angiogenic factors in prognosis and hypothesize how they can be used as a treatment target.
Literatur
1.
2.
Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer Clin. 2009;59:225–49.CrossRef
3.
4.
5.
Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904–10.CrossRefPubMed
6.
Kishimoto T. Interleukin-6: from basic science to medicine 40 years in immunology. Annu Rev Immunol. 2005;23:1–21.CrossRefPubMed
7.
Oshima Y, Yajima S, Yamazaki K, et al. Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg. 2010;16:389–93.PubMed
8.
Xu Z, Wang S, Wu M, et al. TGF beta1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesis. Oncol Lett. 2013;6:401–6.CrossRefPubMedPubMedCentral
9.
Sugiura K, Ozawa S, Kitagawa Y, et al. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal cancer. World J Gastroenterol. 2005;11:2188–92.CrossRef
10.
Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 1986;11:467–73.
11.
Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004;14:207–14.CrossRefPubMed
12.
Kimura S, Kitadai Y, Tanaka S, et al. Expression of hypoxia inducible factor (HIF)-1α is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004;40:1904–12.CrossRefPubMed
13.
Birchmeier C, Birchmeier W, Gherardi E, et al. Metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.CrossRefPubMed
14.
Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–4.CrossRefPubMed
15.
Ren Yi, Cao Brian, Law Simon, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 2005;3:6190–7.CrossRef
16.
Saeki H, Oda S, Kawaguchi H, et al. Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer. 2002;98:8–13.CrossRefPubMed
17.
Zhou YZ, Fang XQ, Li H, et al. Role of serum angiopoietin-2 level in screening for esophageal squamous cell cancer and its precursors. Chin Med J (Engl). 2007;120:1216–9.
18.
19.
20.
Zhao Z-F, Li J-X, Ye Rui, et al. Interleukin-6 as a potential molecular target in esophageal squamous cell carcinoma. Oncol Lett. 2016;11:925–32.CrossRefPubMed
21.
Schindler C, Levy DE, Decker T. JAK-STAT signaling, from interferons to cytokines. J Biol Chem. 2007;282:20059–63.CrossRefPubMed
22.
Michiels C, Minet E, Mottet D, et al. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Radic Biol Med. 2002;1:1231–42.CrossRef
23.
Wang GL, Jiang BH, Rue EA, et al. Hypoxia inducible factor 1 is a basic helix-loop-helix–PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;1:5510–4.CrossRef
24.
Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 1998;394:485–90.CrossRefPubMed
25.
Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211–20.CrossRefPubMed
26.
Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677–84.CrossRefPubMed
27.
Dibbens JA, Miller DL, Damert A, et al. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell. 1999;10:907–19.CrossRefPubMedPubMedCentral
28.
Ellis LM, Liu W, Fan F, et al. Role of angiogenesis inhibitors in cancer treatment. Oncology (Williston Park). 2001;15:39–46.
29.
Amioka T, Kitadai Y, Tanaka S, et al. Vascular endothelial growth factor- C expression predicts lymph node metastasis of human gastric carcinoma invading the submucosa. Eur J Cancer. 2002;15:1413–9.CrossRef
30.
Zhong H, De Marzo AM, Laughner E, et al. Over-expression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.PubMed
31.
Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;12:2911–6.
32.
Tzao C, Lee S-C, Tung H-J, et al. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers. 2008;25:141–8.CrossRefPubMedPubMedCentral
33.
Olenyuk BZ, Zhang GJ, Klco JM, et al. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA. 2004;101:16768–73.CrossRefPubMedPubMedCentral
34.
Tan C, de Noronha RG, Roecker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005;65:605–12.PubMed
35.
Sandler A. Bevacizumab in non-small cell lung cancer. Clin Cancer Res. 2007;355:4613–6.CrossRef
36.
Samson P, Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. J Gastrointest Oncol. 2017;8(3):418–29.CrossRefPubMedPubMedCentral
37.
38.
Lahm H, Odartchenko N. Role of transforming growth factor β in colorectal cancer. Growth Factors. 1993;9:1–9.CrossRefPubMed
39.
S.-W I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA. 2000;7:9624–9.
40.
Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-β 1 in patients with hepatocellular carcinoma comparison with chronic liver diseases. Cancer (Phila). 1994;73:2275–9.CrossRef
41.
Junker U, Knoefel B, Nuske K, et al. Transforming growth factor-β 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine. 1996;8:794–8.CrossRefPubMed
42.
Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor-β 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375–82.CrossRefPubMed
43.
Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer (Phila). 1999;86:1455–62.CrossRef
44.
Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor-β 1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer (Phila). 2001;92:2985–92.CrossRef
45.
Narai S, Watanabe M, Hasegawa H, et al. Significance of transforming growth factor-β1 as a new tumor marker for colorectal cancer. Int J Cancer. 2002;97:508–11.CrossRefPubMed
46.
Natsugoe S, Xiangming C, Matsumoto M, et al. Smad4 and transforming growth factor-β1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002;8:1838–42.PubMed
47.
Chevallier JM, Vitte E, Derosier C, et al. The thoracic esophagus: sectional anatomy and radiosurgical applications. Surg Radiol Anat. 1991;13:313–21.CrossRefPubMed
48.
Fukuchi M, Miyazaki T, Fukai Y, et al. Plasma level of transforming growth factor-β1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res. 2004;10:2738–41.CrossRefPubMed
49.
Nakamura T, Ozawa S, Kitagawa Y, et al. Expression of basic fibroblast growth factor is associated with a good outcome in patients with squamous cell carcinoma of the esophagus. Oncol Rep. 2005;14:617–23.PubMed
Metadaten
Titel
Angiogenic factors: role in esophageal cancer, a brief review
verfasst von
Kátia Ladeira
Filipa Macedo
Adhemar Longatto-Filho
Sandra F. Martins
Publikationsdatum
16.12.2017
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 2/2018
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-017-0597-1

Weitere Artikel der Ausgabe 2/2018

Esophagus 2/2018 Zur Ausgabe

Original Article

The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma

Original Article

The effects of the herbal medicine Daikenchuto (TJ-100) after esophageal cancer resection, open-label, randomized controlled trial

Original Article

Minimally invasive esophagectomy in the prone position improves postoperative outcomes: role of C-reactive protein as an indicator of surgical invasiveness

Original Article

Treatment selection for esophageal cancer: evaluation from a nationwide database

Original Article

Triple-stapled quadrilateral anastomosis: a new technique for creation of an esophagogastric anastomosis

Original Article

Halofuginone improves caustic-induced oxidative injury of esophagus in rats

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise